The Better Health Company (TBHC), the parent company of the GO Healthy, Egmont Honey, and New Zealand Health Manufacturing businesses will be acquired by Nestle Health Science from CDH Investments and the group's founding shareholders. Nestle Health Science will acquire TBHC in its entirety as part of the transaction. The transaction, according to TBHC chairman Greg Driscoll, was a significant milestone.
"It's a huge vote of confidence in the quality of our products, people, capabilities, and brands." We are extremely proud of what our team has accomplished."
"The reputation of New Zealand as a producer of high-quality food and health products is critical to the success of GO Healthy and Egmont Honey." While the brands' ownership will change, GO Healthy and Egmont Honey will remain proudly New Zealand-made at our Auckland and New Plymouth production sites."
"We are confident that these businesses will continue to grow and develop under new ownership, benefiting from Nestlé Health Science's significant expertise, capital, and networks." The company has excellent growth prospects, particularly in Asia, which will be boosted by a collaboration with a leading global nutrition group such as Nestlé Health Science."
Nestlé Health Science's Head of Oceania, Asia, the Middle East, and Africa, Paul Bruhn, stated that the acquisition is a great strategic fit for the company.
"We are thrilled to be adding TBHC to our regional portfolio." TBHC has built excellent businesses around the GO Healthy and Egmont Honey brands, and with its manufacturing operations, we will be well-positioned to grow these brands even further in collaboration with Nestlé Health Science."
"This is our first acquisition of a company based in Asia, Oceania, or Africa, and we are excited about the opportunities it presents." It fits perfectly with our mission of "empowering healthier lives through nutrition." The transaction's terms have not been disclosed. It is scheduled to be completed in the fourth quarter of 2022. The closing is subject to Overseas Investment Office regulatory approval.
